Towards a Maraviroc long-acting injectable nanoformulation

Tatham, Lee; Savage, Alison C.; Dwyer, Andrew; Siccardi, Marco; Scott, Trevor P.; Vourvahis, Manoli; Clark, Andrew; Rannard, Steve P.; Owen, Andrew

doi:10.1016/j.ejpb.2018.04.009

Cited by 21 publications

(11 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A pharmacokinetic study was done on rats by intramuscularly injecting MVC. It shows that long‐acting injectable MVC is a potential candidate for HIV treatment or prevention . TDF/MVC is a combination of nucleoside reverse transcriptase inhibitor (NRTI) and an entry inhibitor.…”

Section: Entry Inhibitormentioning

confidence: 99%

Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention

Yap

Xin

Tan

et al. 2019

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objectives Antiretroviral agents (ARVs) have been the most promising line of therapy in the management of human immunodeficiency virus (HIV) infections. Some of these ARVs are used in the pre-exposure prophylaxis (PrEP) to suppress the transmission of HIV. Prophylaxis is primarily used in uninfected people, before exposure, to effectively prevent HIV infection. Several studies have shown that ART PrEP prevents HIV acquisition from sexual, blood and mother-to-child transmissions. However, there are also several challenges and limitations to PrEP. This review focuses on the current antiretroviral therapies used in PrEP. Key findings Among ARVs, the most common drugs employed from the class of entry inhibitors are maraviroc (MVC), which is a CCR5 receptor antagonist. Other entry inhibitors like emtricitabine (FTC) and tenofovir (TFV) are also used. Rilpivirine (RPV) and dapivirine (DPV) are the most common drugs employed from the Non-nucleoside reverse transcriptase inhibitor (NNRTIs) class, whereas, tenofovir disoproxil fumarate (TDF) is primarily used in the Nucleoside Reverse Transcriptase Inhibitor (NRTIs) class. Cabotegravir (CAB) is an analog of dolutegravir, and it is an integrase inhibitor. Some of these drugs are also used in combination with other drugs from the same class. Summary Some of the most common pre-exposure prophylactic strategies employed currently are the use of inhibitors, namely entry inhibitors, non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, integrase and protease inhibitors. In addition, we have also discussed on the adverse effects caused by ART in PrEP, pharmacoeconomics factors and the use of antiretroviral prophylaxis in serodiscordant couples.HIV and pre-exposure prophylaxis Pui Khee Yap et al.

show abstract

Section: Entry Inhibitormentioning

confidence: 99%

Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention

Yap

Xin

Tan

et al. 2019

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

“…Long-acting therapeutics require extended drug release, aiming to present patients with therapeutic exposures for weeks/months aer administration. The model dialysis experiments conducted here have been validated in previous studies with different drug compounds to correlate well with in vivo behaviour 11,33 and all show the appearance of the water-soluble parent TFV and the TDF prodrug within the simulated interstitial uid over prolonged periods.…”

mentioning

confidence: 60%

Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Apart from all these novel systems, nanowires, nanofibers, nanoethanosomes and nanofilms are gained their importance in enhancing the oral bioavailability of poorly soluble drugs [33][34][35][36][37][38] . Though the optimizing of several parameters in preparing optimum nano-formulation is bit complicated, several applications like quality by design/ response surface methodology or PAT can be successfully applied [39][40][41][42][43][44] .…”

Section: Novel Technologies In Delivery Of Poorly Soluble Drugsmentioning

confidence: 99%

Novel Approaches to Enhance Oral Bioavailability of Poorly Soluble Drugs

Gowthami

Krishna²,

Rao

2020

Int. J. Res. Pharm. Sci & Tech.

View full text Add to dashboard Cite

Oral administration is considered as major, convenient route among all other routes of delivery, owing to several benefits. But, the poor solubility or enzymatic/metabolic activity are the major concerns in developing a successful formulation. About 40% of approved drugs which are in the current market and 90% of new drug molecules in the developmental pipeline are hydrophobic in nature. The challenge to formulate insoluble drugs has met with various approaches to overcome the problems related to solubility, application of nanotechnology is one amongst them. The present review deals with various nanocarriers and technologies that are proven to be effective in enhancing the bioavilability of poorly soluble drugs.

show abstract

Towards a Maraviroc long-acting injectable nanoformulation

Cited by 21 publications

References 40 publications

Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention

Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention

Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations

Novel Approaches to Enhance Oral Bioavailability of Poorly Soluble Drugs

Contact Info

Product

Resources

About